GYRE Gyre Therapeutics Inc.
Company Analysis
Latest News
🔴 Gyre Therapeutics is trading 28.71% down today — no publicly disclosed cause identified
Gyre Therapeutics is trading at $4.54, down 28.71%, with no publicly disclosed cause identified as of 3:33 p.m. EST on October 30, 2026. - A market-move report...
🔴 Gyre Therapeutics is trading 10% down today with broader market weakness possibly adding pressure
Gyre Therapeutics is trading at $6.38, down 10.01%, with broader market weakness possibly adding pressure; no clear company-specific announcement explains the...
🔴 Gyre Therapeutics is trading 6.35% down today as broader-market weakness may add pressure
Gyre Therapeutics is trading at $6.64, down 6.35%, with no clear company-specific announcement explaining the decline. - The investor-relations page lists...
🔴 Gyre Therapeutics is trading 5% down in after-hours trading with no clear company-specific catalyst
Gyre Therapeutics is trading 5.22% lower at $6.72, with no clear company-specific announcement identified to explain the after-hours decline. - It closed at...
🟢 Gyre Therapeutics is trading 5% up
Gyre Therapeutics is trading 5.21% up at $6.87 on October 28, 2026, with no clear company-specific announcement identified to explain the intraday gain. - The...
🟢 Gyre Therapeutics is trading 6% up today; catalyst remains unclear
Gyre Therapeutics is trading at $6.44 (+6.10%), with the cause of the gain uncertain. - No clear company-specific catalyst for October 27 was identified; the...
🔴 Gyre Therapeutics is trading 5% down today
Gyre Therapeutics is trading at $5.86, down 5.02% during the October 21, 2026 session; no clearly reported company-specific announcement explaining the decline...
🟢 Gyre Therapeutics is trading 9% up in after-hours trading
Gyre Therapeutics is trading 9.03% higher at $6.64 after an after-hours rebound; the catalyst remains unclear. - Price context shows a sharp rebound after...
🔴 Gyre Therapeutics falls 5.2% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🔴 Gyre Therapeutics is trading 5.3% down today as Treasury yields hit highs unseen since 2007
Gyre Therapeutics is trading 5.3% down at $7.01 as biotechnology and growth stocks weaken amid a broader risk-off session. - The 10-year Treasury yield...
🔴 Gyre Therapeutics is trading 5.3% down today as oil and Treasury yields pressured equity valuations
Gyre Therapeutics is trading 5.3% lower at $7.09, apparently amid broader risk-off sentiment as rising oil prices and Treasury yields pressured equity...
🟢 Gyre Therapeutics is trading 5% up today as biotech ETF XBI gains
Gyre Therapeutics is trading 5.01% up now at $7.54, primarily driven by biotech-sector strength. - The move extends the September 17, 2026 close of $7.18,...
🟢 Gyre Therapeutics rises 6.1% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Gyre Therapeutics is trading 5.43% up today
Gyre Therapeutics is trading 5.43% up at $6.79, with no clear catalyst confirmed. - The company announced participation in the Cantor Global Healthcare...
Gyre Therapeutics Provides FY26 Revenue Guidance and Key Pipeline Updates
Gyre Therapeutics released an updated corporate presentation outlining its commercial and clinical strategy, including full-year 2026 revenue guidance for its...
Gyre Therapeutics provides pipeline update, FY26 revenue guidance, and key milestones
Gyre Therapeutics, Inc. released an updated corporate presentation detailing its clinical pipeline, upcoming catalysts, and commercial operations. The company...
🔴 Gyre Therapeutics is trading 5.79% down today after an earnings miss
Gyre Therapeutics is trading at $6.51, down 5.79%, as post-earnings concerns continue to pressure shares. - Its August 7 quarterly loss missed analyst...
Gyre Therapeutics Downgraded to Strong Sell, Following Earnings Miss
Zacks Research downgraded Gyre Therapeutics from hold to strong sell on August 20, 2026. This revision signals a bearish outlook for the company’s near-term...
🔴 Gyre Therapeutics falls 5.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Gyre Therapeutics faces liquidity risks, citing concentrated ownership and loan exposure
An analyst warned today of significant risks for Gyre Therapeutics stock due to thin trading volume. Insiders and GNI Parties maintain a heavy ownership...